BioInvent buys Merck single-use tech to up mAb capacity

By Gareth Macdonald

- Last updated on GMT

BioInvent facility in Lund, Sweden
BioInvent facility in Lund, Sweden

Related tags Biotechnology

BioInvent International AB has acquired a range of different single-use bioreactors from Germany’s Merck to up monoclonal antibody (mAb) capacity at its plant in Lund, Sweden.

The deal – financial terms of which were not provided – will see BioInvent install 3-, 50-, 200- and 1000-liter bioreactors from Merck’s Mobius range at the plant, with the idea being the range of sizes will simplify production scale-up.

Kristoffer Rudenholm Hansson, vice president of Technical Operations at BioInvent, said: “Merck’s single-use bioreactors most effectively addressed our current and future needs with a fully scalable system​.”

BioInvent outlined its plan to increased mAb production capacity last September, citing the expansion of a customer contract as the driver.

At the time, the firm told us it used 500L Wave systems provided by GE Healthcare, but intended to install a 1,000L Single Use bioreactor (SUB).

Related topics Upstream Processing Bioreactors

Related news

Related products

Process optimization for mAb commercial manufacturing

Process optimization for mAb commercial manufacturing

Content provided by Catalent | 01-Jun-2023 | Product Presentation

Process characterization and validation is an important step in the product development journey and late-phase development, and it is required before transferring...